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Abstract
Background: The aim of our study is to study the association between eye lesions in Hereditary Hemorrhagic
Telangiectasia (HHT) and other signs of the disease, as well as to characterize its genetics.
Methods: A cross-sectional study was conducted of a cohort of 206 patients studied in the HHT Unit of Hospital de
Sierrallana, a reference centre for Spanish patients with HHT. Odds ratios for several symptoms or characteristics of
HHT and ocular lesions were estimated using logistic regression adjusting for age and sex.
Results: The ocular involvement was associated with being a carrier of a mutation for the ENG gene, that is,
suffering from a type 1 HHT involvement (OR = 2.09; 95% CI [1.17–3.72]). p = 0.012). In contrast, patients with ocular
lesions have less frequently mutated ACVRL1/ALK1 gene (OR = 0.52; 95% CI [0.30–3.88], p = 0.022).
Conclusions: In conclusion, half of the patients with HHT in our study have ocular involvement. These eye lesions
are associated with mutations in the ENG gene and ACVRL1/ALK1 gene. Thus, the ENG gene increases the risk of
ocular lesions, while being a carrier of the mutated ACVRL1/ALK1 gene decreases said risk.
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Background
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber syndrome is a rare disease that affects be-
tween 5000 to 8000 people worldwide [1], although,
given the clinical variability of the disease and subclinical
forms, it is believed that the figures are underesti-
mated. The HHT presents a wide geographic variabil-
ity, the highest prevalence rate being among the
Afro-Caribbean population of the islands of Curaçao
and Bonaire, with 1 case in 1331 inhabitants due to a
probable founder effect [2].
HHT is characterized by the presence of vascular mal-
formations; its diagnosis is based on Curaçao’s clinical
criteria: recurrent epistaxis, multiple telangiectases in
skin and mucosae, visceral involvement (including, for
instance, arteriovenous malformations in lung, brain or
liver) and first degree relative with HHT. Three or four
criteria need to be fulfilled for the diagnosis to be estab-
lished [3]. HHT is inherited with an autosomal domin-
ant pattern. Approximately 75% of cases are caused by
mutations in the Endoglin (ENG) gene, responsible for
the HHT1 subtype, and ACVRL1ACVRL1/ALK1(activin
A receptor like kinasa type 1), responsible for the HHT2
subtype. About 1–3% of patients with a clinical diagnosis
or 10% of patients with a negative genetic test for ENG
and ACVRL1/ALK1are carriers of mutations in the
MADH4 (mother against decapentaplegic homolog 4)
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gene, that codifies for Smad 4 [4, 5]. The HHT Sub-
type also has geographical preferences, with HHT1
being more frequent in North America [6, 7] and in
northern Europe [8], while HHT2 is more prevalent
in Mediterranean countries like Italy [9, 10], France
[11] and Spain [12].
Although eye involvement is frequent, few studies have
described its characteristics and its relationship with
other HHT features [13–17], and they were purely de-
scriptive. The main goal of this paper is to study the as-
sociation between eye lesions in HHT and other signs of
the disease, as well as to characterize its genetic back-
ground. In order to do it, we carried out a cross-
sectional analysis of a cohort of 206 patients studied in
the HHT Unit of Hospital de Sierrallana, Spain.
Methods
Setting and patients
The study was conducted in the HHT Unit of the
Sierrallana Regional Hospital (Torrelavega, Cantabria),
Spanish national reference centre for HHT. Patients
were included if they have a confirmed diagnosis of
HHT according to Curaçao criteria and/or genetic test
between March 2003 and September 2013. Patients who
do not reside in Spain or without Spanish nationality
have been excluded from the analysis. All patients were
screened by the Ophthalmology Department to assess
the presence of ocular lesions associated with HHT.
All procedures performed in studies involving human
participants were in accordance with the ethical stan-
dards of the institutional and / or national research
committee, and with the 1964 Helsinki Declaration and
its later amendments or comparable ethical standards.
The specific study reported here was approved by the
Ethical Committee of Clinical Research of Cantabria. In-
formed consent was obtained from all individual partici-
pants included in the study.
Diagnosis procedure (Fig. 1)
Patients accomplishing 3 or 4 Curaçao criteria were di-
agnosed as HHT. Patients fulfilling only 1 or 2 Curaçao
criteria were diagnosed as HHT only if they also carried
a mutation in ACVRL1/ALK1, ENG or MADH4 genes.
Genotyping procedure (Fig. 1)
All patients were genotyped searching for mutations in
ACVRL1/ALK1, ENG and MADH4 genes; if all three ge-
notyped were negative, multiplex ligation-dependent
probe amplification (MLPa) techniques were performed
to rule out deletions / insertions in ACVRL1/ALK1 and
ENG. Results of all genetic tests were compared with the
international database of HHT mutations [18] to check
whether they were mutations already described or they
were new.
Ophthalmologic examination
All patients were studied in the Ophthalmology service.
In the ophthalmological examination, the best corrected
visual acuity, the palpebral physical examination and the
anterior ocular segment have been assessed by means of
a slit lamp, including upper eyelid eversion. The ocular
tension was measured by contact tonometry and the
Fig. 1 Location of ocular telangiectasia in patients with HHT
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fundus was explored under mydriasis by indirect
ophthalmoscopy. In case of injuries, these were
photographed.
Other tests
All patients underwent physical examination, family tree
scrutiny and search for vascular malformations by
cerebral MRI angiography, conventional and contrast
(bubbles) echocardiography, conventional abdominal
ultrasound, abdominal Doppler to study hepatic
vascularization and capillaroscopy evaluating megacapil-
laries and microhemorrhages in the nail bed of the 4th
and 3th fingers of the right hand. All patients were stud-
ied in the Otolaryngology service. All patients also re-
ceived the Quality of Life Scale (Euroqol 5D) and
exclusively for women of childbearing age, a lumbar
MRI angiography was also performed.
Other explorations could be carried out depending of
the results of the previous tests, including thoracic CT
with or without intravenous contrast, CT angiography,
abdominal CT and pulmonary angiography.
Statistical analysis
For the description of the main qualitative variables, pro-
portions were used. Quantitative variables were de-
scribed by mean and standard deviation (SD). To
quantify the degree of association between the variables,
raw and age- and sex-adjusted odds ratios (OR) with
their 95% confidence interval (95% CI) were estimated
via logistic regression. In all the statistical tests used, a
value of p < 0.05 was considered statistically significant.
Stata 14 / SE package was used in the analyses.
Results
Characteristics of patients
Table 1 displays demographic characteristics and distri-
bution of ocular involvement. Out of 206 patients with
confirmed HHT, 105 (51%) had ocular telangiectasias on
the examination performed by ophthalmologists. Pa-
tients with ocular involvement were older on average
(50.3 ± 13.5 vs. 44.7 ± 15.7, p = 0.006). Eye lesions did not
affect visual acuity or intraocular pressure. Fifty-five pa-
tients had both eyes affected; most ocular telangiectasias
were located in the tarsal conjunctiva and fewer were lo-
cated in bulbar conjunctiva, lid margin and caruncle; no
lesions were found in retina. Figure 1 shows pictures
with different locations of ocular telangiectasias. Regard-
ing the exploration with slit lamp and ophthalmoscopy,
we found no differences between patients with and with-
out ocular involvement. Eye involvement was not associ-
ated with the accomplished criteria of Curaçao
(Table 2). Regarding the association between the pa-
tient’s personal history and ocular involvement (supple-
mentary Table 1) we observe that there are no
statistically significant differences between patients with
arterial hypertension or diabetes mellitus and ocular in-
volvement. Mutations in ACVRL1/ALK1 gene appeared
in 118 patients (57%) and in Endoglin gene in 77 pa-
tients (37%). Eye involvement was twice as frequent in
patients carrying a mutation in the Endoglin gene than
in patients with mutation on the ACVRL1/ALK1 gene
(Odds ratio [OR] = 2.10, 95% CI: 1.12–3.95) (Table 3).
The more frequent locations for telangiectasias -apart
from conjunctiva- were nose (192, 93%), lips (166, 81%),
mouth (156, 76%) and fingers (128, 62%). Ocular telangi-
ectasias were associated with telangiectasias in fingers
(age and sex adjusted OR = 2.25, 95% CI: 1.21–4.17, p =
0.01), but not with telangiectasias in other locations as
nasal, labial, oral or trunk (Table 4). As with the associ-
ation of ocular involvement and the presence of telangi-
ectasias in the fingers, ocular lesions in HHT have a
significant association with capillaroscopy, multiplying
Table 1 Demographic data and eye involvement of patients
with HHT
Eye involvement No eye involvement p value
Sex
Men 48 (49.5%) 49 (50.5%) 0.69
Women 57 (52.3%) 52 (47.7%)
Age: mean ± sd 50.3 ± 13.5 44.7 ± 15.7 0.006
< 19 years 1 (11.1%) 8 (88.9%) 0.05
20–39 years 24 (45.35) 29 (54.7%)
40–59 years 53 (55.2%) 43 (44.8%)
60–79 years 27 (56.3%) 21 (43.7%)
Visual acuity: mean ± sd
Right eye 0.90 ± 0.17 0.93 ± 0.18 0.26
Left eye 0.88 ± 0.22 0.94 ± 0.21 0.11
Intraocular pressure: mean ± sd
Right eye 15.40 ± 2.15 15.80 ± 2.17 0.32
Left eye 15.21 ± 2.05 15.66 ± 2.03 0.24









Eyelid location of telangiectasias: patients (no. of eyes)
Upper and lower 18 (30)
Upper 32 (42)
Lower 23 (32)
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by 2.26 the possibility of presenting a positive result
(OR = 2.26; IC95% [1.20–4.27] p = 0.004). This probabil-
ity decreases if we adjust for age and sex (OR = 1.99;
IC95% [1.04–3.81]) but remains significant (Supplemen-
tary Table 4).
In relation to the association of ocular involvement
with bleeding in locations other than epistaxis, signifi-
cant association has been found only with bleeding from
lesions at the mouth (age and sex adjusted OR = 2.16;
95% CI: 1.18–3.97, p = 0.01) and at the skin of the nose
(age and sex adjusted OR = 2.90, 95% CI 1.60–5.26 p =
0.001), but not with bleeding in skin, digestive tract or
central nervous system (Supplementary Table 2). The re-
lation between eye involvement and epistaxis / nasal tel-
angiectasias is displayed in Supplementary Table 3. Eye
telangiectasias were associated with grade II intensity
epistaxis (age and sex adjusted OR = 2.03, 95% CI: 1.04–
3.97, p = 0.04) and with nasal telangiectasias grade (p for
trend = 0.001); nasal telangiectasias grade III (branched
telangiectasias) (age and sex adjusted OR = 2.52, 95% CI:
1.00–6.34, p = 0.05) and grade IVa (isolated vascular
malformations) (age and sex OR = 3.84, 95% CI: 1.20–
12.3, p = 0.02) displayed significant associations with
ocular involvement. Finally, Supplementary Table 4
shows the association between pulmonary involvement
and ocular telangiectasias. Pulmonary lesions were asso-
ciated with ocular telangiectasias either when studied by
bubble contrast echocardiography (p for trend = 0.03,
age and sex adjusted OR for grade 4 lesions = 3.92, 95%
CI: 1.25–12.3, p = 0.02), computerized tomography angi-
ography (age and sex adjusted OR = 1.99, 95% CI: 0.98–
4.02, p = 0.06) or pulmonary angiography (age and sex
adjusted OR = 20, 95% CI: 2.42–165.5, p = 0.005), al-
though the last result was based in just 25 explorations.
Discussion
According to our results, ocular involvement in Spanish
HHT patients is more frequent in people with mutations
in the endoglin gene, which is responsible for HHT sub-
type 1 (HHT1), than in patients with mutations in the
ACVRL1/ALK1 gene, responsible for HHT subtype 2
(HHT2). HHT1 has been associated with higher fre-
quency of arteriovenous malformations located in lungs
or in brain, while patients with HHT2 are more fre-
quently affected of telangiectasias in the liver [19]. Co-
herently, we have found that ocular manifestations of
HHT are associated with lung involvement as measured
via bubble contrast echocardiography or computed
tomography-angiography, thus ocular telangiectasias
could serve as a non-invasive marker of HHT manifesta-
tions in the respiratory tract. Other signs of HHT sever-
ity, such as oral bleeding, telangiectasias in the nostril,
grade of nasal telangiectasias and epistaxis intensity are
also associated with ocular telangiectasias, according to
Table 2 Eye involvement association with diagnostic criteria of Curaçao
Curaçao criteria Eye involvement No eye involvement
Telangiectasias No 0 (0%) 0 (0%)
Yes 105 (100%) 101 (100%)
Epistaxis No 1 (0.95%) 3 (2.97%)
Yes 104 (99.05%) 98 (97.03%)
Visceral lesions No 22 (20.95%) 27 (26.63%)
Yes 83 (79.05%) 74 (73.27%)
First degree relative affected No 1 (0.9%) 1 (1.0%)
Yes 104 (99.1%) 100 (99.0%)
N ° criteria 1 0 (0%) 0 (0%)
2 0 (0%) 1 (1.0%)
3 24 (22.9%) 29 (28.7%)
4 81 (77.1%) 71 (70.3%)
Table 3 Eye involvement and genetic mutations
Gene Eye involvement (n = 105) No eye involvement (n = 101) OR (95% CI) p
ACVRL1/ALK1 52 (49.5%) 66 (65.3%) 1 (reference) –
ENG 48 (45.7%) 29 (28.7%) 2.10 (1.12–3.95) 0.01
MADH4 1 (1.0%) 0 (0%) – –
No mutation founded 4 (3.8%) 6 (5.9%) 0.85 (0.17–3.79) 0.80
ACVRL1: Activin A receptor like kinase type 1. ENG: Endoglin. MADH4 (Mother against decapentaplegic homolog 4). OR: Odds ratio. CI: Confidence interval
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our results. In this regard Bergh et al., found that HHT1
subtype patients suffer of larger congenital lesions and,
thus, they considered HHT 1 as a more severe pheno-
type [20]. On the other hand, Lesca et al. [21] studied
the association of telangiectasias in lips, fingers, tongue,
and nose, finding a high penetration in HHT1 with a
greater number of telangiectasias in this subtype. These
findings are in agreement with our results. In this same
way, presumably there is an association between abnor-
mal capillaroscopy and ocular involvement in our study
because capillaroscopy is more altered in HHT1 [1].
In the only previous study analysing the relationship
between conjunctival telangiectasias and HHT subtype
[22], the percentages of patients with conjunctival in-
volvement were 13.4% for HHT1 subtype and 14.6% for
HHT2 subtype, which disagrees with our results. How-
ever, the ocular exploration in that study was not per-
formed by ophthalmologists, which makes its prevalence
values of ocular disease not completely comparable to
ours. Other studies that have found mucocutaneous tel-
angiectasias were unrelated to genetic mutations, either
did not specify the telangiectasias location or studied
them only in typical mucocutaneous locations that are
considered in the Curaçao criteria, i.e., they did not con-
sider ocular involvement [4, 19–21, 23].
Besides that, in our study, the type of ocular lesion
presented by patients with HHT are mainly telangiecta-
sias or conjunctival vascular malformations with low rate
of symptoms and only 1.12% prevalence of retinal in-
volvement. However, we have not found any patient with
retinal lesion. One of the reasons for our low retinal
prevalence may be due to the fact that in the ophthal-
mology unit the new optical coherence tomography
modality, angiographic, was not available, which could
have allowed detailed study of retinal and even choroid
vascularization, without the needing of using contrast.
Therefore, subtle vascular retinal abnormalities may
have been overlooked in the subjects who did not have
fundoscopic abnormalities and, consequently, were not
examined by fluorescein angiography (FA) (which is an
invasive test, relegated to specific cases). However, rela-
tively well preserved visual acuity in our cohort of par-
ticipants could support that there were no retinal lesions
or, as a recent article with OCT-Angiography and wide-
field angiography data from 24 eyes has revealed, that in-
traocular lesions in patients with HHT predominantly
affect peripheral vasculature, while retinal vascular dis-
eases, such as diabetes and age-related macular degener-
ation, typically affect the more metabolically active
central vasculature of the retina [16]. Indirect ophthal-
moscopy could have not been accurate enough to rule
out the presence of discrete peripheral retinal telangiec-
tasias, which can only be easily seen by UWF-FA. How-
ever, UWF-FA is an invasive test not indicated in our
patients and OCT-Angiography was not available on the
dates of our study. Further research with this tech-
nique in a greater number of subjects with HHT
would be necessary to more accurately assess the
presence of retinal lesions. Further research with this
technique in a greater number of subjects with HHT
would be necessary to more accurately assess the
presence of retinal lesions. In addition, it is note-
worthy that telangiectasias seem to have predilection
for certain organs, the conjunctiva being the most af-
fected location in the eye instead of other more vas-
cularized locations such as the choroid.
Table 4 Association of ocular telangiectasias with telangiectasias in other locations
Telangiectasia location Eye involvement (yes/total) OR (95% CI) p ORa (95% CI) p
Facial No 41/96 1 (Reference) 1 (Reference)
Yes 64/110 1.87 (1.07–3.25) 0.03 1.45 (0.78–2.69) 0.24
Nasal No 5/14 1 (Reference) 1 (Reference)
Yes 100/192 1.96 (0.63–6.05) 0.24 1.45 (0.46–4.64) 0.53
Lip No 15/40 1 (Reference) 1 (Reference)
Yes 90/166 1.97 (0.97–4.01) 0.06 1.67 (0.80–3.47) 0.17
Oral No 22/50 1 (Reference) 1 (Reference)
Yes 83/156 1.45 (0.76–2.75) 0.26 1.07 (0.53–2.14) 0.85
Fingers No 28/78 1 (Reference) 1 (Reference)
Yes 77/128 2.70 (1.51–4.83) 0.001 2.25 (1.21–4.17) 0.01
Trunk No 93/178 1 (Reference) 1 (Reference)
Yes 12/28 0.69 (0.31–1.53) 0.36 0.67 (0.30–1.53) 0.35
Arms No 101/202 1 (Reference) 1 (Reference)
Yes 4/4 – –
OR Odds ratio, CI Confidence interval, ORa Odds ratio adjusted for age at onset and sex
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This study has some strengths. Firstly, all patients in-
cluded in this study have a confirmed genetic diagnosis
and have been followed by professionals specialized in
the manifestations of the disease and its management.
When Vase and Vase [17], in 1979, and Brant et al. [13]
in 1989 carried out their studies on the prevalence of
ocular involvement in HHT, the diagnostic criteria of
Curaçao had not been established and the techniques of
current genetic diagnosis were not available, so the num-
ber of patients diagnosed with HHT in their studies does
not fit the current diagnostic criteria of the disease. Sec-
ondly, the HHT Unit of Hospital de Sierrallana is a ref-
erence centre for Spanish patients with HHT and the
ophthalmological examination is included in the routine
protocol of the HHT Unit; therefore, patients included
in our study have not been selected because of suspicion
of ocular involvement, which rules out selection bias. In
addition, participation of ophthalmologists in one previ-
ous study in 2007 on ocular involvement [14] was car-
ried out through questionnaires that had been submitted
to the research centre.
In our series of 206 patients there are 105 patients
with ocular lesions, so the prevalence of ocular involve-
ment in our HHT population is 51%. Three studies that
analysed the clinical characteristics in populations of
high prevalence of HHT provided much lower preva-
lence of conjunctival involvement, with values of 1%
[24], 14% [22] and 16% [2]. However, these studies do
not include the participation of ophthalmologists. On
the other hand, five comparable prevalence studies have
been published in the literature [13–17] with case series
of 20, 75, 8, 18 and 43, patients respectively, who have
been examined by ophthalmologists, so that our study
represents the one with the highest number of cases
published to date. These studies estimate the prevalence
of ocular involvement at 43% [17], 35% [13] and 38%
[14] for conjunctival lesions and 2, 10 and 0% for retinal
lesions. Notice there is a big difference between the
prevalence values of ocular involvement between studies
published in the literature. This highlights the import-
ance of a good examination by an ophthalmologist to
confirm or rule out the existence of ocular lesions re-
lated to HHT. In addition, according to our data, pa-
tients with ocular telangiectasias were older; although,
the natural history of vascular malformations in HHT
patients is not well understood, this result suggests
that ocular telangiectasias may appear in later stages
of HHT [16].
Conclusions
Half of the patients with HHT in our study have ocular
involvement. The type of ocular lesion that our patients
present are mainly conjunctival telangiectasias with low
rate of symptoms and are associated with HHT 1
subtype and several signs of disease severity. In addition,
as the probability of eye involvement subject to mutation
in ENG is higher than that in ALK1 (62.34% vs. 44.07%),
we suggest starting the genetic sequencing with ENG if
mutated, or ALK1 otherwise. Further studies are needed
to confirm these results, which suggest ocular telangiec-
tasias could be a non-invasive marker of severity in
HHT.
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